Drug Trial Radar · NCT00492726
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
Last checked: Nov 20, 2026Latest source record: Nov 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
804
Actual
Start
Jul 2006
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 27, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.
Conditions
- Infection
Interventions
Moxifloxacin (Avelox, BAY12-8039)Drug
Moxifloxacin, 400mg, administered intravenously once daily
Ertapenem intravenousDrug
Active treatment: Ertapenem 1.0g, administered intravenously once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol PopulationTime frame: 21 to 28 days after completion of study drug therapy
Locations
52 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Capital Federal, Argentina
Site not named
Ciudadela, Buenos Aires, Argentina
Site not named
De Febrero 3, Buenos Aires, Argentina
Site not named
Merlo, Buenos Aires, Argentina
Site not named
San Juan Bautista, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Córdoba, Córdoba Province, Argentina
Site not named
Mendoza, Mendoza Province, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Bruxelles - Brussel, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Ghent, Belgium
Site not named
Pleven, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Kohtla-Järve, Estonia
Site not named
Tallinn, Estonia
Site not named
Tartu, Estonia
Site not named
Amilly, France
Site not named
Besançon, France
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Site not named
Beeskow, Brandenburg, Germany
Site not named
Hanover, Lower Saxony, Germany
Site not named
Paderborn, North Rhine-Westphalia, Germany
Site not named
Homburg, Saarland, Germany
Site not named
Rio Patras, Greece
Site not named
Haifa, Israel
Site not named
Kfar Saba, Israel
Site not named
Daugavpils, Latvia
Site not named
Liepāja, Latvia
Site not named
Rēzekne, Latvia
Site not named
Riga, Latvia
Site not named
Riga, Latvia
Site not named
Valmiera, Latvia
Site not named
Kaunas, Lithuania
Site not named
Klaipėda, Lithuania
Site not named
Vilnius, Lithuania
Site not named
Vilnius, Lithuania
Site not named
Brasov, Romania
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.